Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma Fraga Dias, Amanda de Dallemole, Danieli Rosane Bruinsmann, Franciele Aline Lopes Silva, Luiz Fernando Cruz López, Olga Conejo-García, Ana Oliveira Battastini, Ana María Campos Rosa, Joaquín María Stanisçaski Guterres, Silvia Raffin Pohlmann, Adriana Figueiró, Fabrício Aim: To develop and characterize bozepinib-loaded lipid-core nanocapsules (BZP-LNC+) as a potential treatment for glioblastoma (GBM). Methods: Characterization of nanocapsules was performed by diameter, polydispersity index, zeta potential, pH and encapsulation efficiency. GBM cell viability, cell cycle and Annexin/PI were evaluated after BZP-LNC+ treatment. Synergism between BZP-LNC+ and temozolomide (TMZ) was performed by CompuSyn software and confirmed in vitro and in vivo. Results: BZP-LNC+ showed adequate particle sizes, positive zeta potential, narrow size distribution and high encapsulation efficiency. BZP-LNC+ reduces GBM growth by inducing apoptosis. BZP-LNC+ and TMZ showed synergistic effect in vitro and reduced the in vivo glioma growth by approximately 81%. Conclusion: The present study provides proof-of-principle insights for the combination of these drugs for GBM treatment. 2024-01-23T08:29:56Z 2024-01-23T08:29:56Z 2021-09-15 info:eu-repo/semantics/article https://hdl.handle.net/10481/87126 10.2217/nnm-2021-0164 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional